Literature DB >> 19860654

Immunotherapy of human cancers using gene modified T lymphocytes.

Juan F Vera1, Malcolm K Brenner, Gianpietro Dotti.   

Abstract

Adoptive T cell therapies can produce objective clinical responses in patients with hematologic and solid malignancies. Genetic manipulation of T lymphocytes has been proposed as a means of increasing the potency and range of this anti-tumor activity. We now review how coupling expression of transgenic receptors with countermeasures against potent tumor immune evasion strategies is proving highly effective in pre-clinical models and describe how these approaches are being evaluated in human subjects.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19860654      PMCID： PMC2952647          DOI： 10.2174/156652309789753338

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN： 1566-5232            Impact factor:   4.391


  140 in total

1.  Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8+ T lymphocyte immortalization.

Authors:  M Migliaccio; M Amacker; T Just; P Reichenbach; D Valmori; J C Cerottini; P Romero; M Nabholz
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

2.  Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor.

Authors:  E J Beecham; S Ortiz-Pujols; R P Junghans
Journal:  J Immunother       Date:  2000 May-Jun       Impact factor: 4.456

3.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Authors:  Gianpietro Dotti; Barbara Savoldo; Martin Pule; Karin C Straathof; Ettore Biagi; Eric Yvon; Stephane Vigouroux; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

4.  Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.

Authors:  A Hombach; C Heuser; R Sircar; T Tillmann; V Diehl; C Pohl; H Abken
Journal:  J Immunother       Date:  1999-11       Impact factor: 4.456

5.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

6.  Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

Authors:  Nabil Ahmed; Maheshika Ratnayake; Barbara Savoldo; Laszlo Perlaky; Gianpietro Dotti; Winfried S Wels; Meenakshi B Bhattacharjee; Richard J Gilbertson; H David Shine; Heidi L Weiss; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

Review 7.  TGF-beta and tumors--an ill-fated alliance.

Authors:  Niki M Moutsopoulos; Jie Wen; Sharon M Wahl
Journal:  Curr Opin Immunol       Date:  2008-05-15       Impact factor: 7.486

8.  CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.

Authors:  M Jensen; G Tan; S Forman; A M Wu; A Raubitschek
Journal:  Biol Blood Marrow Transplant       Date:  1998       Impact factor: 5.742

Review 9.  Tumor immune escape mediated by indoleamine 2,3-dioxygenase.

Authors:  Maria Zamanakou; Anastasios E Germenis; Vaios Karanikas
Journal:  Immunol Lett       Date:  2007-07-02       Impact factor: 3.685

10.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Maurilio Ponzoni; Cynthia Bartholomae; Lucia Sergi Sergi; Fabrizio Benedicenti; Alessandro Ambrosi; Clelia Di Serio; Claudio Doglioni; Christof von Kalle; Luigi Naldini
Journal:  Nat Biotechnol       Date:  2006-05-28       Impact factor: 54.908
View more
  13 in total

1.  Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?

Authors:  Adham S Bear; Richard A Morgan; Kenneth Cornetta; Carl H June; Gwendolyn Binder-Scholl; Mark E Dudley; Steven A Feldman; Steven A Rosenberg; Sheila A Shurtleff; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti
Journal:  Mol Ther       Date:  2012-02       Impact factor: 11.454

2.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 3.  Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

Review 4.  Immunotherapy prospects for acute myeloid leukaemia.

Authors:  A J Barrett; K Le Blanc
Journal:  Clin Exp Immunol       Date:  2010-05-31       Impact factor: 4.330

Review 5.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

6.  Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

Authors:  C Sanchez; R Chan; P Bajgain; S Rambally; G Palapattu; M Mims; C M Rooney; A M Leen; M K Brenner; J F Vera
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-01-08       Impact factor: 5.554

7.  Engineered T cells for pancreatic cancer treatment.

Authors:  Usha L Katari; Jacqueline M Keirnan; Anna C Worth; Sally E Hodges; Ann M Leen; William E Fisher; Juan F Vera
Journal:  HPB (Oxford)       Date:  2011-07-20       Impact factor: 3.647

Review 8.  Novel immunotherapies for hematologic malignancies.

Authors:  Michelle H Nelson; Chrystal M Paulos
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

9.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

10.  Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells.

Authors:  Sadhak Sengupta; Ilya V Ulasov; Bart Thaci; Atique U Ahmed; Maciej S Lesniak
Journal:  PLoS One       Date:  2011-03-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.